Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development.

Antibody drug conjugates (ADCs) are clinically active in several cancers, but their relevance in cholangiocarcinoma (CCA) is undefined. We profiled 23 CCA tumors and found that TROP2 was highly expressed (82.6%) but also present in benign epithelium. NECTIN4 (65.2%) showed tumor-specific staining, supporting selectivity. B7-H3 (47.8%) and CLDN18.2 (13.0%) were less frequently positive. IDH1-mutant tumors demonstrated attenuated ADC target expression. These data provide rationale for evaluating ADC strategies in CCA.